WO2024009307A1 - Viroporins blockers/inhibitors as anti-flaviviruses agents - Google Patents
Viroporins blockers/inhibitors as anti-flaviviruses agents Download PDFInfo
- Publication number
- WO2024009307A1 WO2024009307A1 PCT/IL2023/050703 IL2023050703W WO2024009307A1 WO 2024009307 A1 WO2024009307 A1 WO 2024009307A1 IL 2023050703 W IL2023050703 W IL 2023050703W WO 2024009307 A1 WO2024009307 A1 WO 2024009307A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flavivirus
- channel blocker
- cell
- west nile
- dengue virus
- Prior art date
Links
- 108700039655 Viroporin Proteins Proteins 0.000 title description 23
- 239000003795 chemical substances by application Substances 0.000 title description 22
- 239000003112 inhibitor Substances 0.000 title description 3
- 230000003441 anti-flavivirus Effects 0.000 title 1
- 241000725619 Dengue virus Species 0.000 claims abstract description 95
- 241000710886 West Nile virus Species 0.000 claims abstract description 65
- 241000710831 Flavivirus Species 0.000 claims abstract description 64
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 101710085938 Matrix protein Proteins 0.000 claims abstract description 27
- 101710127721 Membrane protein Proteins 0.000 claims abstract description 27
- 230000001018 virulence Effects 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 62
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 31
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 29
- 229960002169 plerixafor Drugs 0.000 claims description 28
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 20
- 229960000401 tranexamic acid Drugs 0.000 claims description 20
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 19
- PVTHJAPFENJVNC-MHRBZPPQSA-N kasugamycin Chemical compound N[C@H]1C[C@H](NC(=N)C(O)=O)[C@@H](C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O PVTHJAPFENJVNC-MHRBZPPQSA-N 0.000 claims description 19
- 229960004635 mesna Drugs 0.000 claims description 18
- TVTXCJFHQKSQQM-LJQIRTBHSA-N 4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)[C@H]1[C@H](C=2C(=C(Cl)C=CC=2)F)[C@@](C#N)(C=2C(=CC(Cl)=CC=2)F)[C@H](CC(C)(C)C)N1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 claims description 15
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims description 15
- MLSQGNCUYAMAHD-ITNVBOSISA-N glecaprevir Chemical compound O=C([C@@H]1C[C@H]2OC3=NC4=CC=CC=C4N=C3C(F)(F)/C=C/CO[C@@H]3CCC[C@H]3OC(=O)N[C@H](C(N1C2)=O)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2(C)CC2)C[C@H]1C(F)F MLSQGNCUYAMAHD-ITNVBOSISA-N 0.000 claims description 15
- 229960005322 streptomycin Drugs 0.000 claims description 15
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 14
- 229950008970 glecaprevir Drugs 0.000 claims description 14
- 229950002843 idasanutlin Drugs 0.000 claims description 14
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 13
- 229960002756 azacitidine Drugs 0.000 claims description 13
- 229960002529 benzbromarone Drugs 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims 1
- 108091006146 Channels Proteins 0.000 description 85
- 210000004027 cell Anatomy 0.000 description 73
- 238000003556 assay Methods 0.000 description 71
- 208000036142 Viral infection Diseases 0.000 description 33
- 230000009385 viral infection Effects 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 31
- 239000000203 mixture Substances 0.000 description 30
- 206010012310 Dengue fever Diseases 0.000 description 26
- 208000025729 dengue disease Diseases 0.000 description 26
- 230000012010 growth Effects 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 108090000862 Ion Channels Proteins 0.000 description 13
- 102000004310 Ion Channels Human genes 0.000 description 13
- 206010057293 West Nile viral infection Diseases 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 208000001490 Dengue Diseases 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 150000004677 hydrates Chemical class 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 206010053759 Growth retardation Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 231100000001 growth retardation Toxicity 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 4
- 239000003929 acidic solution Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- -1 CI- 1040 Chemical compound 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 201000006449 West Nile encephalitis Diseases 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 241000256111 Aedes <genus> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 208000011312 Vector Borne disease Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- TVMUHOAONWHJBV-UHFFFAOYSA-N dehydroglycine Chemical compound OC(=O)C=N TVMUHOAONWHJBV-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FCFZKAVCDNTYID-UHFFFAOYSA-M dibenziodolium chloride Chemical compound [Cl-].C1=CC=C2[I+]C3=CC=CC=C3C2=C1 FCFZKAVCDNTYID-UHFFFAOYSA-M 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940040939 repurposed drug Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Definitions
- the present invention is in the field of anti-viral therapy.
- the genus Flaviviruses belongs to the Flaviviridae family of enveloped positivestrand RNA viruses. It includes several important arboviral pathogens that represent a specific health burden, such as dengue virus, West Nile virus, Zika virus, yellow fever virus, and tick-borne encephalitis, to name a few. Dengue fever, as an example, is transmitted by Aedes mosquitos and exacts an appreciable toll with ca. 40,000 annual deaths stemming from 390 million infections and half a million hospitalizations. Despite the fact that risk of infection exists in 129 countries, 70% of the actual burden is in Asia. According to World Health Organization (WHO) dengue cases has been increased 8 fold over past two decades.
- WHO World Health Organization
- West Nile fever transmitted by Culex mosquitos, is another cause of concern. Identified in Kenya in 1937, it is now spread globally. Since its discovery in 1999, there have been 52,532 cases in the US, of which 25,849 have been neuroinvasive, leading to 2,456 deaths. Consequently, West Nile fever is the leading cause of mosquito -borne disease in the continental US.
- a method of treating or preventing a flavivirus virulence in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a flavivirus M protein channel blocker, thereby treating or preventing flavivirus virulence in the subject.
- a method of preventing flavivirus entry, uncoating and/or release from a cell comprising contacting the cell with a flavivirus M protein channel blocker, thereby preventing a flavivirus cell entry, uncoating and/or release from the cell.
- a pharmaceutical composition comprising a flavivirus M protein channel blocker for use in treating or preventing flavivirus virulence in a subject in need thereof.
- a pharmaceutical composition comprising a flavivirus M protein channel blocker for use in preventing a flavivirus cell entry, uncoating and/or release from a cell.
- the cell is a cell of a subject, and the contacting is administering to the subject.
- the subject is a subject infected or suspected as being infected by a flavivirus virulence.
- the flavivirus is a Dengue virus
- the flavivirus M protein channel blocker is a Dengue virus DPI channel blocker.
- the flavivirus is a West Nile virus
- the flavivirus M protein channel blocker is a West Nile virus MgM channel blocker.
- the Dengue virus DPI channel blocker is at least one molecule selected from the group consisting of: plerixafor, glecaprevir streptomycin, mesna, kasugamycin, tranexamic acid, CI- 1040, or a salt thereof.
- the West Nile virus MgM channel blocker is at least one molecule selected from the group consisting of: idasanutlin, benzbromarone, 5 -azacytidine, and plerixafor, or a salt thereof.
- the flavivirus M protein channel blocker is for use at a daily dose of 0.01 to 500 mg/kg.
- the pharmaceutical composition comprises a Dengue virus DPI channel blocker for use in treating or preventing Dengue virulence in a subject in need thereof.
- the pharmaceutical composition comprises a West Nile virus MgM channel blocker for use in treating or preventing West Nile virulence in a subject in need thereof.
- the pharmaceutical composition comprises a Dengue virus DPI channel blocker for use in preventing a Dengue virus cell entry, uncoating and/or release from a cell.
- the pharmaceutical composition comprises a West Nile virus MgM channel blocker for use in preventing a West Nile virus cell entry, uncoating and/or release from a cell.
- Figure 1 includes bar graphs demonstrating a negative assay of Dengue Virus DPI and West Nile Virus MgM viroporins. Maximal growth rates of DH10B bacteria expressing each viroporin are depicted as a function of the inducer concentration (IPTG).
- Figures 2A-2D include bar graphs demonstrating a positive assay of Dengue Virus DPI and West Nile Virus MgM viroporins.
- (2A-2B) Maximal growth rates of K + -uptake deficient bacteria expressing each viroporin, monitored as a function of different K + concentrations. Growth enhancement can be observed upon comparing induced and uninduced bacteria in orange and blue, respectively.
- (2C-2D) Growth rates at different inducer concentrations (IPTG), as noted.
- Figure 3 includes graphs showing an acidity assay of Dengue Virus DPI and West Nile Virus MgM viroporins. Cytoplasmic H + concentration is monitored as a function of time whereby at time 0, an acidic solution is injected into the media. Results are shown from bacteria in which viroporin induction is changed a as function of IPTG concentration as noted.
- Figures 4A-4F include graphs showing blocker screening results against Dengue Virus DPI and West Nile Virus MgM viroporins.
- the negative assay results are depicted in (4A) and (4B), whereas the results from the positive assay are presented in (4C) and (4D).
- the acidity assay results are presented in (4E) and (4F).
- Bacteria in which the channel expression was not induced, or the drug was not added were used as controls. Blocker concentration was 50 pM.
- Figures 5A-5D include graphs showing blocker screening results against Dengue Virus DPI and West Nile Virus MgM viroporins. Maximal growth rates are depicted as a function of different compound concentrations (0.78-100 pM), as noted in the color legend. Bacteria in which the channel expression was not induced, or the drug was not added were used as controls.
- (5A-5B) Negative assay results for Dengue Virus DPI and West Nile Virus MgM viroporins, respectively.
- 5C-5D Positive assay results for Dengue Virus DPI and West Nile Virus MgM viroporins, respectively.
- Figure 6 includes curves showing inhibitory constants of blocker screening results against Dengue Virus DPI (left column) and West Nile Virus MgM (right column) viroporins using the negative assays (as provided in Figures 5A-5B). Normalized growth enhancements are depicted as a function of different compound concentrations (0.78-100 pM). Bacteria in which the channel expression was not induced or the drug was not added are used as controls. The inhibitory constants are listed in each panel as well as the fitting coefficient.
- Figures 7A-7B include a three-dimensional bar graph demonstrating blocker combinations against (7A) West Nile Virus MgM viroporins and (7B) Dengue Virus DPI. Results from the negative assay in which active blockers should improve growth rate relative to untreated samples. Different combinations are presented according to the color scale on the left and numerically on the right. Each drug was at 100 pM. Diagonal values in white indicate individual treatments.
- the present invention in some embodiments, provides compositions comprising a M protein channel blocker for treating or preventing a flavivirus virulence in a subject.
- the present invention in some embodiments, provides compositions comprising a flavivirus M protein channel blocker for preventing flavivirus cell entry, uncoating and/or release from a cell.
- a flavivirus comprises a Dengue virus.
- the M (membrane) protein of a Dengue virus is termed herein “DPI” (Dengue Pl).
- the present invention provides compositions comprising a DPI protein channel blocker for treating or preventing Dengue virus virulence in a subject.
- the present invention in some embodiments, provides compositions comprising a DPI protein channel blocker for preventing Dengue virus cell entry, uncoating and/or release from a cell.
- a flavivirus comprises a West Nile virus.
- the M protein of West Nile virus is termed herein “MgM”.
- the present invention provides compositions comprising a MgM protein channel blocker for treating or preventing West Nile virus virulence in a subject.
- the present invention in some embodiments, provides compositions comprising a MgM protein channel blocker for preventing West Nile virus cell entry, uncoating and/or release from a cell.
- the present invention provides that Dengue virus DPI is an ion channel.
- the invention in some embodiments, is further based, at least in part, on a finding that at least one molecule selected from: mesna, kasugamycin, glecaprevir, plerixafor, CI- 1040, streptomycin, tranexamic acid, or any combination thereof, inhibits Dengue virus DPI, and therefore, can be used to treat and/or prevent Dengue virus virulence.
- the invention in some embodiments, is further based, at least in part, on a finding that at least one molecule selected from: plerixafor, glecaprevir, streptomycin, mesna, and kasugamycin, or any combination thereof, increased cell viability (e.g., of a mammalian cell) upon Dengue virus infection, and therefore, can be used to treat and/or prevent Dengue virus virulence. Further, tranexamic acid was found to increase, at least partially, the viability of a mammalian cell upon infection of Dengue virus. [037] The present invention, according to three bacteria-based assays, provides that West Nile virus MgM is an ion channel.
- the invention in some embodiments, is further based, at least in part, on a finding that at least one molecule selected from: benzbromarone, idasanutlin, 5-azacytidine, and plerixafor, or any combination thereof, inhibited West Nile virus MgM, and therefore, can be used to treat and prevent West Nile virus virulence.
- Dengue virus DPI is disclosed under GenBank Accession no: NP_722459.2.
- DPI diphenyl glycoprotein
- Mg membrane glycoprotein
- Dengue virus DPI comprises the amino acid sequence:
- the Dengue virus DPI comprises an analog of SEQ ID NO: 1, having at least 85%, at least 90%, at least 95% sequence identity or homology thereto, or any value and range therebetween. Each possibility represents a separate embodiment of the invention. According to some embodiments, the DPI comprises an analog of SEQ ID NO: 1 having homology within the range of: 85-100%, 91-100%, and 96- 100%. Each possibility represents a separate embodiment of the invention.
- West Nile virus MgM is disclosed under GenBank Accession no: YP_001527879.1. According to some embodiments, the West Nile virus MgM comprises the amino acid sequence:
- the West Nile virus MgM comprises an analog of SEQ ID NO: 2, having at least 85%, at least 90%, at least 95% sequence identity or homology thereto, or any value and range therebetween. Each possibility represents a separate embodiment of the invention. According to some embodiments, the West Nile virus MgM comprises an analog of SEQ ID NO: 2 having homology within the range of: 85-100%, 91- 100%, and 96-00%. Each possibility represents a separate embodiment of the invention.
- analog refers to a polypeptide that is similar, but not identical, to the polypeptide of the invention that still is capable of binding succinate or still comprises the succinate binding pocket.
- An analog may have deletions or mutations that result in an amino acids sequence that is different than the amino acid sequence of the polypeptide of the invention. It should be understood that all analogs of the polypeptide of the invention would still be capable of generating an ion channel. Further, an analog may be analogous to a fragment of the polypeptide of the invention, however, in such a case the fragment must comprise at least 30 consecutive amino acids of the polypeptide of the invention.
- the invention provides a method of treating or preventing a flavivirus virulence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a flavivirus M protein channel blocker, thereby treating or preventing a flavivirus virulence in the subject.
- the invention provides a method of treating or preventing a Dengue virulence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a Dengue virus DPI channel blocker, thereby treating or preventing a Dengue virulence in the subject.
- the invention provides a method of treating or preventing a West Nile virulence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a West Nile MgM channel blocker, thereby treating or preventing a West Nile virulence in the subject.
- the invention provides a method of preventing a flavivirus release from a cell, the method comprising contacting the cell with a flavivirus M protein channel blocker, thereby preventing a flavivirus release from the cell.
- the invention provides a method of preventing a Dengue virus release from a cell, the method comprising contacting the cell with Dengue virus DPI channel blocker, thereby preventing a dengue virus release from the cell.
- the invention provides a method of preventing a West Nile virus release from a cell, the method comprising contacting the cell with West Nile virus MgM channel blocker, thereby preventing a West Nile virus release from the cell.
- the invention provides a method of preventing a flavivirus cell entry, the method comprising contacting the cell with a flavivirus M protein channel blocker, thereby preventing a flavivirus cell entry.
- the invention provides a method of preventing a Dengue virus cell entry, the method comprising contacting the cell with a Dengue virus DPI channel blocker, thereby preventing a Dengue virus cell entry.
- the invention provides a method of preventing a West Nile virus cell entry, the method comprising contacting the cell with a West Nile virus MgM channel blocker, thereby preventing a West Nile virus cell entry.
- the invention provides a method of preventing a flavivirus uncoating, the method comprising contacting the cell with a flavivirus M channel blocker, thereby preventing a flavivirus uncoating.
- the invention provides a method of preventing a Dengue virus uncoating, the method comprising contacting the cell with a Dengue virus DPI channel blocker, thereby preventing a Dengue virus uncoating.
- the invention provides a method of preventing a West Nile virus uncoating, the method comprising contacting the cell with a West Nile virus MgM channel blocker, thereby preventing a West Nile virus uncoating.
- the cell is a cell of a subject. According to some embodiments, contacting is administering to the subject. According to some embodiments, the subject is a subject infected or suspected as being infected by a Dengue virus. According to other embodiments, the subject is a subject infected or suspected as being infected by a West Nile virus.
- the flavivirus M channel blocker is at least one molecule selected from: plerixafor or a salt thereof, streptomycin or a salt thereof, tranexamic acid or a salt thereof, CI- 1040 or a salt thereof, glecaprevir or a salt thereof, kasugamycin, or a salt thereof, mesna or a salt thereof, idasanutlin or a salt thereof, benzbromarone or a salt thereof, 5-azacytidine or a salt thereof, or any combination thereof.
- the Dengue virus DPI channel blocker is at least one molecule selected from: plerixafor or a salt thereof, streptomycin or a salt thereof, tranexamic acid or a salt thereof, CI- 1040 or a salt thereof, glecaprevir or a salt thereof, kasugamycin, or a salt thereof, mesna or a salt thereof, or any combination thereof.
- the West Nile virus MgM channel blocker is at least one molecule selected from: idasanutlin or a salt thereof, benzbromarone or a salt thereof, 5-azacytidine or a salt thereof, plerixafor or a salt thereof, or any combination thereof.
- the invention provides a Dengue virus DPI channel blocker for use in treating or preventing a Dengue virulence in a subject in need thereof.
- the invention provides a West Nile virus MgM channel blocker for use in treating or preventing a West Nile virulence in a subject in need thereof.
- the Dengue Virus DPI blocker comprises a combination comprising tranexamic acid and mesna. In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising kasugamycin and CI- 1040. In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising kasugamycin and tranexamic acid. In some embodiments, the combination of Dengue Virus DPI blocker comprises, exhibits, or characterized by additivity of the individual Dengue Virus DPI blockers. In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising plerixafor and at least one additional Dengue Virus DPI blocker.
- the Dengue Virus DPI blocker comprises a combination comprising plerixafor and at least one molecule selected from: streptomycin, tranexamic acid, CI- 1040, glecaprevir, kasugamycin, mesna, or any combination thereof.
- a Dengue virus DPI channel blocker comprises any salt thereof.
- the invention provides a Dengue virus DPI channel blocker for use in preventing Dengue virus release from a cell.
- the invention provides a West Nile virus MgM channel blocker for use in preventing West Nile virus release from a cell.
- the Dengue virus DPI channel blocker is within a pharmaceutical composition, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
- the West Nile virus MgM channel blocker is within a pharmaceutical composition, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
- the invention provides a pharmaceutical composition comprising plerixafor, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a Dengue virus infection.
- the viral infection comprises West Nile virus infection.
- the viral infection comprises an infection by a virus comprising a flavivirus M protein.
- the viral infection comprises an infection by a flavivirus comprising a Dengue virus DPI protein.
- the viral infection comprises an infection by a flavivirus comprising a West Nile virus MgM protein.
- the Dengue virus DPI channel blocker comprises plerixafor, an analog or a salt thereof.
- the West Nile virus channel blocker comprises plerixafor, an analog or a salt thereof.
- Plerixafor includes plerixafor (CAS: 110078-46-1, IUPAC: l-[[4- (1,4,8,11 -tetrazacyclo tetradec - 1 -y Imethy l)pheny 1] methyl] -1,4,8,11- tetrazacyclotetradecane), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- Plerixafor is described, for example, in U.S. Patent US20200268850A1.
- the invention provides a pharmaceutical composition comprising streptomycin, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a Dengue virus infection.
- the viral infection comprises an infection by virus having a dengue virus DPI being an ion channel.
- the Dengue virus DPI channel blocker comprises streptomycin, an analog or a salt thereof.
- Streptomycin includes streptomycin (CAS: 57-92-1, IUPAC: 2- [(17?,27?,3S,47?,57?,6S)-3-(diaminomethylideneamino)-4-[(27?,37?,47?,55')-3- [(2S,3S,4S,57?,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4- formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising tranexamic acid, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a Dengue virus infection.
- the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
- the Dengue virus DPI channel blocker comprises tranexamic acid an analog or a salt thereof.
- Tranexamic acid includes tranexamic acid (CAS: 701-54-2, IUPAC: 4-(aminomethyl)cyclohexane- 1 -carboxylic acid), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising CI- 1040, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a Dengue virus infection.
- the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
- the Dengue virus DPI channel blocker comprises CI- 1040, an analog or a salt thereof.
- CI-1040 includes CI-1040 (CAS: 212631-79-3, IUPAC: 2-(2-chloro- 4-iodoanilino)-A-(cyclopropylmethoxy)-3,4-difluorobenzamide), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising glecaprevir, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a Dengue virus infection.
- the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
- the Dengue virus DPI channel blocker comprises glecaprevir, an analog or a salt thereof.
- Glecaprevir includes glecaprevir (CAS: 1365970-03-1; IUPAC: (l/?,14E,18/?,22/?,265,295)-26-fert-butyl-A-[(l/?,2/?)-2-(difluoromethyl)-l-[(l- methylcyclopropyl) sulfonylcarbamoyl] cyclopropyl] -13,13 -difluoro-24,27 -dioxo-2, 17,23- trioxa-4,l l,25,28-tetrazapentacyclo[26.2.1.0 3 ’ 12 .0 5 ’ 10 .0 18 ’ 22 ] hentriaconta-3,5,7,9,11,14- hexaene-29-carboxamide), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising kasugamycin, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a Dengue virus infection.
- the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
- the Dengue virus DPI channel blocker is kasugamycin, an analog or a salt thereof.
- Kasugamycin includes kasugamycin (CAS: 6980-18-3; IUPAC: 2- amino-2-[(27?,3S,5S,67?)-5-amino-2-methyl-6-[(27?,3S,5S,6S)-2,3,4,5,6- pentahydroxycyclohexyl]oxyoxan-3-yl]iminoacetic acid), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising mesna, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a Dengue virus infection.
- the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
- the Dengue virus DPI channel blocker comprises mesna, an analog or a salt thereof.
- Mesna as used herein, includes mesna (CAS: 19767-45-4; IUPAC: sodiumssulf any lethanesulfonate), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising idasanutlin, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a West Nile virus infection.
- the viral infection comprises an infection by virus having a West Nile MgM being an ion channel.
- the West Nile MgM channel blocker comprises idasanutlin, an analog or a salt thereof.
- Idasanutlin includes idasanutlin (CAS: 1229705-06-9; IUPAC: 4- [[(27?,3S,47?,5S)-3-(3-chloro-2-fhiorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2- dimethylpropyl)pyrrolidine-2-carbonyl] amino] -3 -methoxybenzoic acid), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising benzbromarone, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a West Nile virus infection.
- the viral infection comprises an infection by virus having a West Nile MgM being an ion channel.
- the West Nile MgM channel blocker comprises benzbromarone, an analog or a salt thereof.
- Benzbromarone as used herein, includes benzbromarone (CAS: 3562-84-3; IUPAC: (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-l-benzofuran-3-yl)methanone), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- the invention provides a pharmaceutical composition comprising 5-azacytidine, an analog or a salt thereof, for treating a viral infection.
- the viral infection comprises a West Nile virus infection.
- the viral infection comprises an infection by virus having a West Nile MgM being an ion channel.
- the West Nile MgM channel blocker is 5- azacytidine, an analog or a salt thereof.
- 5 -Azacytidine includes 5-azacytidine (CAS: 320-67-2; IUPAC: 4- amino-l-[(27?,37?,4S,5S)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
- treatment encompasses alleviation of at least one symptom thereof, a reduction in the severity thereof, or inhibition of the progression thereof. Treatment need not mean that the disease, disorder, or condition is totally cured.
- a useful composition herein needs only to reduce the severity of a disease, disorder, or condition, reduce the severity of symptoms associated therewith, or provide improvement to a patient or subject’s quality of life.
- administering refers to any method which, in sound medical practice, delivers a composition containing an active agent to a subject in such a manner as to provide a therapeutic effect.
- the terms “subject” or “individual” or “animal” or “patient” or “mammal” refers to any subject, particularly a mammalian subject, for whom therapy is desired, for example, a human.
- a therapeutically effective dose of the composition of the invention is administered.
- therapeutically effective amount refers to an amount of a drug effective to treat a disease or disorder in a mammal.
- a therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. The exact dosage form and regimen would be determined by the physician according to the patient's condition.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- the route of administration of the pharmaceutical compositions will depend on the disease or condition to be treated. Suitable routes of administration include, but are not limited to, parenteral injections, e.g., intradermal, intravenous, intramuscular, intralesional, subcutaneous, intrathecal, and any other mode of injection as known in the art.
- compositions of the invention can be lower than when administered via parenteral injection, by using appropriate compositions it is envisaged that it will be possible to administer the compositions of the invention via transdermal, oral, rectal, vaginal, topical, nasal, inhalation and ocular modes of treatment.
- the composition of the invention comprising oral delivery.
- the composition of the invention comprises an oral composition.
- the composition of the invention further comprises orally acceptable carrier, excipient, or a diluent.
- the Dengue virus DPI channel blocker is for use at a daily dose of 0.01 to 500 mg/kg.
- the West Nile virus MgM channel blocker is for use at a daily dose of 0.01 to 500 mg/kg.
- the Dengue virus DPI channel blocker comprises plerixafor or a salt thereof and is for use at a daily dose between about 0.1 mg/kg/day and about 10 mg/kg/day, 0.1 mg/kg/day and 5 mg/kg/day, and 0.1 mg/kg/day and 1 mg/kg/day.
- the Dengue virus DPI channel blocker comprises streptomycin or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 100 mg/day, about 5 mg/kg/day and 60 mg/kg/day, and 10 mg/kg/day and 40 mg/kg/day.
- the Dengue virus DPI channel blocker comprises tranexamic acid or a salt thereof and is for use at a daily dose of between about 1 mg//kg/day and about 100 mg/kg/day, about 1 mg/kg/day and 50 mg/kg/day, and 5 mg/kg/day and 40 mg/kg/day.
- the Dengue virus DPI channel blocker comprises CI- 1040 or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 500 mg/kg/day, about 5 mg/kg/day and 400 mg/kg/day, and 40 mg/kg/day and 200 mg/kg/day.
- the Dengue virus DPI channel blocker comprises glecaprevir or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 150 mg/kg/day, about 10 mg/kg/day and 100 mg/kg/day, and 1 mg/day and 10 mg/kg/day.
- the Dengue virus DPI channel blocker comprises kasugamycin or a salt thereof and is for use at a daily dose of between about 1 mg/day and about 100 mg/kg/day, about 5 mg/kg/day and 50 mg/kg/day, and 10 mg/kg/day and 40 mg/kg/day.
- the Dengue virus DPI channel blocker comprises mesna or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 100 mg/kg/day, about 5 mg/kg/day and 80 mg/kg/day, and 5 mg/kg/day and 50 mg/kg/day.
- the West Nile virus MgM channel blocker comprises plerixafor or a salt thereof and is for use at a daily dose between about 0.1 mg/kg/day and about 10 mg/kg/day, 0.1 mg/kg/day and 5 mg/kg/day, and 0.1 mg/kg/day and 1 mg/kg/day.
- the West Nile virus MgM channel blocker comprises idasanutlin or a salt thereof and is for use at a daily dose of between about 10 mg/kg/day and about 100 mg/kg/day, about 10 mg/kg/day and 50 mg/kg/day, and 5 mg/kg/day and 40 mg/kg/day.
- the West Nile virus MgM channel blocker comprises benzbromarone or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 200 mg/kg/day, about 2 mg/kg/day and 150 mg/kg/day, and 3 mg/kg/day and 100 mg/kg/day.
- the West Nile virus MgM channel blocker comprises 5-azacytidine or a salt thereof and is for use at a daily dose of between about 0.5 mg/kg/day and about 500 mg/day, about 1 mg/kg/day and 200 mg/day, and 1 mg/day and 100 mg/day.
- the pharmaceutical composition comprises a pharmaceutically acceptable carrier, adjuvant, or excipient.
- carrier refers to any component of a pharmaceutical composition that is not the active agent.
- pharmaceutically acceptable carrier refers to non-toxic, inert solid, semi-solid liquid filler, diluent, encapsulating material, formulation auxiliary of any type, or simply a sterile aqueous medium, such as saline.
- sugars such as lactose, glucose and sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin, talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol, polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline, Ringer's solution; ethy
- substances which can serve as a carrier herein include sugar, starch, cellulose and its derivatives, powered tragacanth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols, alginic acid, pyrogen-free water, isotonic saline, phosphate buffer solutions, cocoa butter (suppository base), emulsifier as well as other non-toxic pharmaceutically compatible substances used in other pharmaceutical formulations.
- Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, stabilizers, antioxidants, and preservatives may also be present.
- any non- toxic, inert, and effective carrier may be used to formulate the compositions contemplated herein.
- Suitable pharmaceutically acceptable carriers, excipients, and diluents in this regard are well known to those of skill in the art, such as those described in The Merck Index, Thirteenth Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, N.J. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association) International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004); and the “Inactive Ingredient Guide,” U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Management, the contents of all of which are hereby incorporated by reference in their entirety.
- CTFA Cosmetic, Toiletry, and Fragrance Association
- Examples of pharmaceutically acceptable excipients, carriers and diluents useful in the present compositions include distilled water, physiological saline, Ringer's solution, dextrose solution, Hank's solution, and DMSO. These additional inactive components, as well as effective formulations and administration procedures, are well known in the art and are described in standard textbooks, such as Goodman and Gillman’s: The Pharmacological Bases of Therapeutics, 8th Ed., Gilman et al. Eds. Pergamon Press (1990); Remington’s Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa.
- compositions may also be contained in artificially created structures such as liposomes, ISCOMS, slow-releasing particles, and other vehicles which increase the half-life of the peptides or polypeptides in serum.
- liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like.
- Liposomes for use with the presently described peptides are formed from standard vesicle-forming lipids which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol.
- the selection of lipids is generally determined by considerations such as liposome size and stability in the blood.
- a variety of methods are available for preparing liposomes as reviewed, for example, by Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York, and see also U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
- the carrier may comprise, in total, from about 0.1% to about 99.99999% by weight of the pharmaceutical compositions presented herein.
- a method of screening effectiveness of an agent in treating or preventing a Dengue virus infection comprising providing a cell comprising a membrane permeabilized with Dengue DPI, contacting the cell with the agent, and determining effect of the agent on growth of the cell, wherein a substantial effect of the agent on cellular growth is indicative of the agent as being effective for treating or preventing a Dengue virus infection, thereby screening effectiveness of an agent in treating or preventing a Dengue virus infection.
- the method comprises a negative assay.
- the cell is characterized by growth retardation due to the membrane permeabilized with Dengue DPI.
- an agent that alleviates growth retardation is indicative as being effective for treating or preventing a Dengue virus infection.
- the method comprises a positive assay.
- the cell is a K + -uptake deficient cell grown in low [K + ] media experience growth, due to the channel formed by a Dengue DPI.
- an agent that induces growth retardation is indicative as being effective for treating or preventing a Dengue virus infection.
- the method comprises performing both the negative assay and the positive assay.
- the method further comprises an acidity assay.
- the cell is a pH-sensitive cell comprising a reporter gene or a protein product thereof, such as, but not limited to, green fluorescent protein (GFP).
- GFP green fluorescent protein
- an agent that elevates pH (reduces acidity) within the pH- sensitive cell is suitable for treating or preventing a Dengue virus infection.
- a method of screening effectiveness of an agent in treating or preventing a West Nile virus infection comprising providing a cell comprising a membrane permeabilized with West Nile MgM, contacting the cell with the agent, and determining effect of the agent on growth of the cell, wherein a substantial effect of the agent on cellular growth is indicative of the agent as being effective for treating or preventing a West Nile virus infection, thereby screening effectiveness of an agent in treating or preventing a West Nile virus infection.
- the method comprises a negative assay.
- the cell is characterized by growth retardation due to the membrane permeabilized with West Nile MgM.
- an agent that alleviates growth retardation is indicative as being effective for treating or preventing a West Nile virus infection.
- the method comprises a positive assay.
- the cell is a K + -uptake deficient cell grown in low [K + ] media experience growth, due to the channel formed by a West Nile MgM.
- an agent that induces growth retardation is indicative as being effective for treating or preventing a West Nile virus infection.
- the method comprises performing both the negative assay and the positive assay.
- the method further comprises an acidity assay.
- the cell is a pH-sensitive cell comprising a reporter gene or a protein product thereof, such as, but not limited to, green fluorescent protein (GFP).
- GFP green fluorescent protein
- an agent that elevates pH (reduces acidity) within the pH- sensitive cell is suitable for treating or preventing a West Nile virus infection.
- Non-limiting examples for growing a bacterial cell applicable for the screening methods provided herein include: Astrahan, P. et al., Acta 1808, 394-8 (2011); Santner, P. et al. Biochemistry 57, 5949-5956 (2016), and Taube, R., Alhadeff, R., Assa, D., Krugliak, M. & Arkin, I. T. PLoS One 9, el05387 (2014).
- the assay comprises determining susceptibility of the virus to develop resistance against the agent.
- a length of about 1,000 nanometers (nm) refers to a length of 1,000 nm ⁇ 100 nm.
- Bacteria cultures were grown overnight and finally diluted 500 fold and again set to grow until their O.D.600 reached 0.2. From the culture 50 pl were added in 96- well flat-bottomed plates which was pre-treated with 50 pl of required staff. Induction was achieved by employing different concentration of isopropyl-P-d-1 -thiogalactopyranoside.
- a multi-plate incubator infinite M200 pro from Tecan Group; Mannedorf, Switzerland or LogPhase 600 from BioTek; Santa Clara, CA, USA was used to incubate the plates for 16 hours at 37 °C at a constant, shaking rate (700 rpm). Bacterial growth was monitored by measuring O.D.600 every 15 min. Duplicates, or triplicates were conducted for every measurement.
- the positive assay employed the same protocol as the negative assay was but in this instance a K + -uptake deficient bacteria strain was used . Additionally, overnight growth was conducted in LB media in which 100 mM KC1 replaced NaCl.
- the acidity assay is based on bacteria expressing a chromosomal copy of a pH sensitive GFP. Overnight bacterial cultures were diluted to 1:500 in LB media and subsequently grown to an O.D.600 of 0.6-0.8. Protein expression was induced by isopropyl- P-D-l- thiogalactopyranoside at different concentrations, as noted. After one hour of induction, the cells were diluted to an O.D.600 of 0.2 and pelleted at 3500 g for 10 min. Subsequently, the cells were resuspended in McILvaine Buffer, which contains 200 mM Na2HPO4 and 0.9% NaCl adjusted to pH 7.6 with 0.1 M citric acid.
- a chemical library of 2,839 compounds was purchased from MedChem Express (HY- L035, Monmouth Junction, NJ, USA). All chemicals were screened at 100 pM using the negative screening at first, whereby 100 pM isopropyl-P-D-l-thiogalactopyranoside was used to induce DPI and MgM expression. Bacteria without isopropyl-P-D-1- thiogalactopyranoside (z.e., no protein induction) were used as a positive control, while bacteria that received only DMSO served as the negative control. Drugs that increased bacterial growth up to a certain threshold were selected for further duplicate analyses.
- drugs that passed duplicate analysis in the negative assays were examined by positive assay, where 5 pM and 10 pM isopropyl-P-D-l-thiogalactopyranoside were used to induce DPI and MgM expression, respectively.
- Compounds that passed the negative and positive assays were subjected to dose-response analyses and fluorescence-based assays.
- the negative assay tested the additive effects of drugs by employing equal concentrations of all possible combinations.
- Isopropyl-P-d-1 -thiogalactopyranoside was purchased from Biochemika-Fluka (Buchs, Switzerland). All other chemicals were purchased from Sigma- Aldrich laboratories (Rehovot, Israel).
- Lysogeny broth was used for most of the cases only LBK was used for positive assay, where NaCl is replaced with KCL at lOgm/lt. All media contained ampicilin at 100 g/ml.
- Vero E6 cells were tested in the presence of Dengue virus (type 1, BC89/94).
- Cells were infected with a muliplicity of infection (MOI) of 3, and their viability was monitored by MTS post five days of infection.
- MOI muliplicity of infection
- different drugs were added (each diluted in 0.1% DMSO) at a concentration of 10 pM. Results were normalized relative to uninfected cells (100%) and cells that received only 0.1% DMSO (0%).
- bacteria-based assays in which the channel’s functionality changes the bacteria’s phenotype.
- the advantages of the assays are that they are amenable to high-throughput screening, and the ease of genetic manipulations in bacteria enables a rapid transition from one sequence/variant to another.
- these assays have been tested on numerous viroporins from various viruses (Assa, D. et al. J Mol Biol 2016, 428, 4209-4217, Astrahan, P. et al. 2011, 1808, 394-398, Taube, R, PLoS One 2014, 9, el05387, Tomar, P.P.S. et al.
- the first assay used to characterize both viroporins is one in which the protein is expressed at increasing levels in bacteria. As seen in other channels, elevated expression levels are detrimental to bacterial growth due to excessive permeabilization of the bacterial inner membrane. Therefore, in this assay, the viral protein eponymously impacts bacteria negatively.
- the second bacteria-based assay that was employed was reciprocal in nature to the negative assay listed above.
- K + -uptake deficient bacteria are incapable of growing in regular bacteriological media unless it is enriched with potassium.
- the bacteria are able to thrive in low K + media if they express a channel capable K + transport. Hence, in this instance the activity of the channel impacts growth positively.
- the final assay that was employed measured H + conductivity by using bacteria that express a pH-sensitive GFP.
- an acidic solution is injected into the media while monitoring bacterial fluorescence that is indicative of its cytoplasmic pH. A change in fluorescence would indicate H + - flux due to a channel conductivity.
- Results shown in Figure 3 demonstrate that both viroporins were able to facilitate H + transport with Dengue Virus DPI exhibiting higher activity than West Nile Virus MgM.
- FIGS. 4A-4B The results of the negative assay screen are shown Figures 4A-4B in which seven blockers were identified against Dengue Virus DPI and four against West Nile Virus MgM. Subsequently, the positive assay was employed to examine the potency of the hits identified in the negative assay: out of the seven blockers active against Dengue Virus DPI, four were shown to be active in the positive assay, conducted herein ( Figure 4C). In contrast, all hits in the negative assay against West Nile Virus MgM were confirmed in the positive assay ( Figure 4D).
- the final step in the screening process involved dose-response analyses of the compounds that passed the negative and positive assays for each viroporin: plerixafor, streptomycin, tranexamic acid, and CI-1040 against Dengue Virus DPI, and idasanutlin, benzbro-marone, 5-azacytidine, and plerixafor against West Nile Virus MgM.
- the results are depicted in Figures 5A-5D, and the fitted inhibitory contestants are provided in Figure 6.
- the inventors next sought to determine potential additivity or synergism between the different hits. To that end, they examined all possible combinations of drugs that were active against Dengue Virus DPI and West Nile Virus MgM channels in equal concentrations. From Figure 7B it can be seen that several Dengue Virus DPI blocker combinations, like tranexamic acid + mesna, kasugamycin + CI- 1040, and kasugamycin + tranexamic acid exhibited additivity. Tranexamic acid + mesna in particular, demonstrated 98% enhancement of growth, whereas the impact of individual components was lower (32% and 82% for tranexamic acid and mesna, respectively).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical compositions including a flavivirus M protein channel blocker for treating or preventing virulence of a flavivirus, such as, Dengue virus and West Nile virus in a subject, are provided. Further provided is a pharmaceutical composition including a blocker of a flavivirus M protein channel, such as DPI and MgM, for preventing flavivirus cell entry, uncoating and/or release from a cell.
Description
VIROPORINS BLOCKERS/INHIBITORS AS ANTI-FLA VIVIRUSES AGENTS
REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[001] The contents of the electronic sequence listing (VRB -P-003 -PCT ST26.xml; size: 2,936 bytes; and date of creation: July 3, 2023) is herein incorporated by reference in its entirety.
CROSS-REFERENCE TO RELATED APPLICATIONS
[002] This application claims the benefit of priority of U.S. Provisional Patent Application No. 63/358,659, titled “VIROPORINS BLOCKERS/INHIBITORS AS ANTIFLA VIVIRUSES AGENTS”, filed 6 July 2022, the contents of which are incorporated herein by reference in their entirety.
FIELD OF INVENTION
[003] The present invention is in the field of anti-viral therapy.
BACKGROUND
[004] The genus Flaviviruses belongs to the Flaviviridae family of enveloped positivestrand RNA viruses. It includes several important arboviral pathogens that represent a specific health burden, such as dengue virus, West Nile virus, Zika virus, yellow fever virus, and tick-borne encephalitis, to name a few. Dengue fever, as an example, is transmitted by Aedes mosquitos and exacts an appreciable toll with ca. 40,000 annual deaths stemming from 390 million infections and half a million hospitalizations. Despite the fact that risk of infection exists in 129 countries, 70% of the actual burden is in Asia. According to World Health Organization (WHO) dengue cases has been increased 8 fold over past two decades.
[005] West Nile fever, transmitted by Culex mosquitos, is another cause of concern. Identified in Uganda in 1937, it is now spread globally. Since its discovery in 1999, there have been 52,532 cases in the US, of which 25,849 have been neuroinvasive, leading to 2,456 deaths. Consequently, West Nile fever is the leading cause of mosquito -borne disease in the continental US.
[006] No antiviral drugs are currently approved against flaviviruses, reducing treatment options to supportive care. There is an urgent need for methods and compounds for ameliorating or treating flaviviruses, such as Dengue fever and West Nile fever.
SUMMARY
[007] According to a first aspect, there is provided a method of treating or preventing a flavivirus virulence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a flavivirus M protein channel blocker, thereby treating or preventing flavivirus virulence in the subject.
[008] According to another aspect, there is provided a method of preventing flavivirus entry, uncoating and/or release from a cell, the method comprising contacting the cell with a flavivirus M protein channel blocker, thereby preventing a flavivirus cell entry, uncoating and/or release from the cell.
[009] According to another aspect, there is provided a pharmaceutical composition comprising a flavivirus M protein channel blocker for use in treating or preventing flavivirus virulence in a subject in need thereof.
[010] According to another aspect, there is provided a pharmaceutical composition comprising a flavivirus M protein channel blocker for use in preventing a flavivirus cell entry, uncoating and/or release from a cell.
[Oi l] In some embodiments, the cell is a cell of a subject, and the contacting is administering to the subject.
[012] In some embodiments, the subject is a subject infected or suspected as being infected by a flavivirus virulence.
[013] In some embodiments, the flavivirus is a Dengue virus, and the flavivirus M protein channel blocker is a Dengue virus DPI channel blocker.
[014] In some embodiments, the flavivirus is a West Nile virus, and the flavivirus M protein channel blocker is a West Nile virus MgM channel blocker.
[015] In some embodiments, the Dengue virus DPI channel blocker is at least one molecule selected from the group consisting of: plerixafor, glecaprevir streptomycin, mesna, kasugamycin, tranexamic acid, CI- 1040, or a salt thereof.
[016] In some embodiments, the West Nile virus MgM channel blocker is at least one molecule selected from the group consisting of: idasanutlin, benzbromarone, 5 -azacytidine, and plerixafor, or a salt thereof.
[017] In some embodiments, the flavivirus M protein channel blocker is for use at a daily dose of 0.01 to 500 mg/kg.
[018] In some embodiments, the pharmaceutical composition comprises a Dengue virus DPI channel blocker for use in treating or preventing Dengue virulence in a subject in need thereof.
[019] In some embodiments, the pharmaceutical composition comprises a West Nile virus MgM channel blocker for use in treating or preventing West Nile virulence in a subject in need thereof.
[020] In some embodiments, the pharmaceutical composition comprises a Dengue virus DPI channel blocker for use in preventing a Dengue virus cell entry, uncoating and/or release from a cell.
[021] In some embodiments, the pharmaceutical composition comprises a West Nile virus MgM channel blocker for use in preventing a West Nile virus cell entry, uncoating and/or release from a cell.
[022] Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
[023] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[024] Figure 1 includes bar graphs demonstrating a negative assay of Dengue Virus DPI and West Nile Virus MgM viroporins. Maximal growth rates of DH10B bacteria expressing each viroporin are depicted as a function of the inducer concentration (IPTG).
[025] Figures 2A-2D include bar graphs demonstrating a positive assay of Dengue Virus DPI and West Nile Virus MgM viroporins. (2A-2B) Maximal growth rates of K+-uptake deficient bacteria expressing each viroporin, monitored as a function of different K+ concentrations. Growth enhancement can be observed upon comparing induced and
uninduced bacteria in orange and blue, respectively. (2C-2D) Growth rates at different inducer concentrations (IPTG), as noted.
[026] Figure 3 includes graphs showing an acidity assay of Dengue Virus DPI and West Nile Virus MgM viroporins. Cytoplasmic H+ concentration is monitored as a function of time whereby at time 0, an acidic solution is injected into the media. Results are shown from bacteria in which viroporin induction is changed a as function of IPTG concentration as noted.
[027] Figures 4A-4F include graphs showing blocker screening results against Dengue Virus DPI and West Nile Virus MgM viroporins. The negative assay results are depicted in (4A) and (4B), whereas the results from the positive assay are presented in (4C) and (4D). The acidity assay results are presented in (4E) and (4F). Bacteria in which the channel expression was not induced, or the drug was not added were used as controls. Blocker concentration was 50 pM.
[028] Figures 5A-5D include graphs showing blocker screening results against Dengue Virus DPI and West Nile Virus MgM viroporins. Maximal growth rates are depicted as a function of different compound concentrations (0.78-100 pM), as noted in the color legend. Bacteria in which the channel expression was not induced, or the drug was not added were used as controls. (5A-5B) Negative assay results for Dengue Virus DPI and West Nile Virus MgM viroporins, respectively. (5C-5D) Positive assay results for Dengue Virus DPI and West Nile Virus MgM viroporins, respectively.
[029] Figure 6 includes curves showing inhibitory constants of blocker screening results against Dengue Virus DPI (left column) and West Nile Virus MgM (right column) viroporins using the negative assays (as provided in Figures 5A-5B). Normalized growth enhancements are depicted as a function of different compound concentrations (0.78-100 pM). Bacteria in which the channel expression was not induced or the drug was not added are used as controls. The inhibitory constants are listed in each panel as well as the fitting coefficient.
[030] Figures 7A-7B include a three-dimensional bar graph demonstrating blocker combinations against (7A) West Nile Virus MgM viroporins and (7B) Dengue Virus DPI. Results from the negative assay in which active blockers should improve growth rate relative to untreated samples. Different combinations are presented according to the color scale on the left and numerically on the right. Each drug was at 100 pM. Diagonal values in white indicate individual treatments.
[031] Figure 8 includes a vertical bar graphs showing cell viability of mammalian cells (Vero E6 cells) after 5 days post infection with Dengue virus. Drug concentration = 10 pM, and multiplicity of infection = 3.
DETAILED DESCRIPTION
[032] The present invention, in some embodiments, provides compositions comprising a M protein channel blocker for treating or preventing a flavivirus virulence in a subject. The present invention, in some embodiments, provides compositions comprising a flavivirus M protein channel blocker for preventing flavivirus cell entry, uncoating and/or release from a cell.
[033] In some embodiments, a flavivirus comprises a Dengue virus. In some embodiments, the M (membrane) protein of a Dengue virus is termed herein “DPI” (Dengue Pl). In some embodiments, the present invention provides compositions comprising a DPI protein channel blocker for treating or preventing Dengue virus virulence in a subject. The present invention, in some embodiments, provides compositions comprising a DPI protein channel blocker for preventing Dengue virus cell entry, uncoating and/or release from a cell.
[034] In some embodiments, a flavivirus comprises a West Nile virus. In some embodiments, the M protein of West Nile virus is termed herein “MgM”. In some embodiments, the present invention provides compositions comprising a MgM protein channel blocker for treating or preventing West Nile virus virulence in a subject. The present invention, in some embodiments, provides compositions comprising a MgM protein channel blocker for preventing West Nile virus cell entry, uncoating and/or release from a cell.
[035] The present invention, according to three bacteria-based assays, provides that Dengue virus DPI is an ion channel. The invention, in some embodiments, is further based, at least in part, on a finding that at least one molecule selected from: mesna, kasugamycin, glecaprevir, plerixafor, CI- 1040, streptomycin, tranexamic acid, or any combination thereof, inhibits Dengue virus DPI, and therefore, can be used to treat and/or prevent Dengue virus virulence.
[036] The invention, in some embodiments, is further based, at least in part, on a finding that at least one molecule selected from: plerixafor, glecaprevir, streptomycin, mesna, and kasugamycin, or any combination thereof, increased cell viability (e.g., of a mammalian cell) upon Dengue virus infection, and therefore, can be used to treat and/or prevent Dengue virus virulence. Further, tranexamic acid was found to increase, at least partially, the viability of a mammalian cell upon infection of Dengue virus.
[037] The present invention, according to three bacteria-based assays, provides that West Nile virus MgM is an ion channel. The invention, in some embodiments, is further based, at least in part, on a finding that at least one molecule selected from: benzbromarone, idasanutlin, 5-azacytidine, and plerixafor, or any combination thereof, inhibited West Nile virus MgM, and therefore, can be used to treat and prevent West Nile virus virulence.
[038] In some embodiments, Dengue virus DPI is disclosed under GenBank Accession no: NP_722459.2.
[039] The terms “DPI” and “membrane glycoprotein (Mg) of Dengue virus” are used herein interchangeably.
[040] According to some embodiments, Dengue virus DPI comprises the amino acid sequence:
SVALAPHVGLGLETRTETWMSSEGAWKQIQKVETWALRHPGFTVIALFLAHAIGT SITQKGIIFILLMLVTPSMA (SEQ ID NO: 1).
[041] According to some embodiments, the Dengue virus DPI comprises an analog of SEQ ID NO: 1, having at least 85%, at least 90%, at least 95% sequence identity or homology thereto, or any value and range therebetween. Each possibility represents a separate embodiment of the invention. According to some embodiments, the DPI comprises an analog of SEQ ID NO: 1 having homology within the range of: 85-100%, 91-100%, and 96- 100%. Each possibility represents a separate embodiment of the invention.
[042] In some embodiments, West Nile virus MgM is disclosed under GenBank Accession no: YP_001527879.1. According to some embodiments, the West Nile virus MgM comprises the amino acid sequence:
SLTVQTHGESTLANKKGAWMDSTKATRYLVKTESWILRNPGYALVAAVIGWML GSNTMQRVVFVV LLLLVAPAYS (SEQ ID NO: 2).
[043] According to some embodiments, the West Nile virus MgM comprises an analog of SEQ ID NO: 2, having at least 85%, at least 90%, at least 95% sequence identity or homology thereto, or any value and range therebetween. Each possibility represents a separate embodiment of the invention. According to some embodiments, the West Nile virus MgM comprises an analog of SEQ ID NO: 2 having homology within the range of: 85-100%, 91- 100%, and 96-00%. Each possibility represents a separate embodiment of the invention.
[044] The term “analog” as used herein, refers to a polypeptide that is similar, but not identical, to the polypeptide of the invention that still is capable of binding succinate or still comprises the succinate binding pocket.
[045] An analog may have deletions or mutations that result in an amino acids sequence that is different than the amino acid sequence of the polypeptide of the invention. It should be understood that all analogs of the polypeptide of the invention would still be capable of generating an ion channel. Further, an analog may be analogous to a fragment of the polypeptide of the invention, however, in such a case the fragment must comprise at least 30 consecutive amino acids of the polypeptide of the invention.
[046] According to some embodiments, the invention provides a method of treating or preventing a flavivirus virulence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a flavivirus M protein channel blocker, thereby treating or preventing a flavivirus virulence in the subject.
[047] According to some embodiments, the invention provides a method of treating or preventing a Dengue virulence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a Dengue virus DPI channel blocker, thereby treating or preventing a Dengue virulence in the subject.
[048] According to some embodiments, the invention provides a method of treating or preventing a West Nile virulence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a West Nile MgM channel blocker, thereby treating or preventing a West Nile virulence in the subject.
[049] According to some embodiments, the invention provides a method of preventing a flavivirus release from a cell, the method comprising contacting the cell with a flavivirus M protein channel blocker, thereby preventing a flavivirus release from the cell.
[050] According to some embodiments, the invention provides a method of preventing a Dengue virus release from a cell, the method comprising contacting the cell with Dengue virus DPI channel blocker, thereby preventing a dengue virus release from the cell.
[051] According to some embodiments, the invention provides a method of preventing a West Nile virus release from a cell, the method comprising contacting the cell with West Nile virus MgM channel blocker, thereby preventing a West Nile virus release from the cell.
[052] According to some embodiments, the invention provides a method of preventing a flavivirus cell entry, the method comprising contacting the cell with a flavivirus M protein channel blocker, thereby preventing a flavivirus cell entry.
[053] According to some embodiments, the invention provides a method of preventing a Dengue virus cell entry, the method comprising contacting the cell with a Dengue virus DPI channel blocker, thereby preventing a Dengue virus cell entry.
[054] According to some embodiments, the invention provides a method of preventing a West Nile virus cell entry, the method comprising contacting the cell with a West Nile virus MgM channel blocker, thereby preventing a West Nile virus cell entry.
[055] According to some embodiments, the invention provides a method of preventing a flavivirus uncoating, the method comprising contacting the cell with a flavivirus M channel blocker, thereby preventing a flavivirus uncoating.
[056] According to some embodiments, the invention provides a method of preventing a Dengue virus uncoating, the method comprising contacting the cell with a Dengue virus DPI channel blocker, thereby preventing a Dengue virus uncoating.
[057] According to some embodiments, the invention provides a method of preventing a West Nile virus uncoating, the method comprising contacting the cell with a West Nile virus MgM channel blocker, thereby preventing a West Nile virus uncoating.
[058] According to some embodiments, the cell is a cell of a subject. According to some embodiments, contacting is administering to the subject. According to some embodiments, the subject is a subject infected or suspected as being infected by a Dengue virus. According to other embodiments, the subject is a subject infected or suspected as being infected by a West Nile virus.
[059] According to some embodiments, the flavivirus M channel blocker is at least one molecule selected from: plerixafor or a salt thereof, streptomycin or a salt thereof, tranexamic acid or a salt thereof, CI- 1040 or a salt thereof, glecaprevir or a salt thereof, kasugamycin, or a salt thereof, mesna or a salt thereof, idasanutlin or a salt thereof, benzbromarone or a salt thereof, 5-azacytidine or a salt thereof, or any combination thereof.
[060] According to some embodiments, the Dengue virus DPI channel blocker is at least one molecule selected from: plerixafor or a salt thereof, streptomycin or a salt thereof, tranexamic acid or a salt thereof, CI- 1040 or a salt thereof, glecaprevir or a salt thereof, kasugamycin, or a salt thereof, mesna or a salt thereof, or any combination thereof.
[061] According to some embodiments, the West Nile virus MgM channel blocker is at least one molecule selected from: idasanutlin or a salt thereof, benzbromarone or a salt thereof, 5-azacytidine or a salt thereof, plerixafor or a salt thereof, or any combination thereof.
[062] According to some embodiments, the invention provides a Dengue virus DPI channel blocker for use in treating or preventing a Dengue virulence in a subject in need thereof. According to some embodiments, the invention provides a West Nile virus MgM
channel blocker for use in treating or preventing a West Nile virulence in a subject in need thereof.
[063] In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising tranexamic acid and mesna. In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising kasugamycin and CI- 1040. In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising kasugamycin and tranexamic acid. In some embodiments, the combination of Dengue Virus DPI blocker comprises, exhibits, or characterized by additivity of the individual Dengue Virus DPI blockers. In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising plerixafor and at least one additional Dengue Virus DPI blocker. In some embodiments, the Dengue Virus DPI blocker comprises a combination comprising plerixafor and at least one molecule selected from: streptomycin, tranexamic acid, CI- 1040, glecaprevir, kasugamycin, mesna, or any combination thereof.
[064] In some embodiments, a Dengue virus DPI channel blocker comprises any salt thereof.
[065] According to some embodiments, the invention provides a Dengue virus DPI channel blocker for use in preventing Dengue virus release from a cell. According to some embodiments, the invention provides a West Nile virus MgM channel blocker for use in preventing West Nile virus release from a cell.
[066] According to some embodiments, the Dengue virus DPI channel blocker is within a pharmaceutical composition, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier. According to some embodiments, the West Nile virus MgM channel blocker is within a pharmaceutical composition, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
[067] According to some embodiments, the invention provides a pharmaceutical composition comprising plerixafor, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a Dengue virus infection. In some embodiments, the viral infection comprises West Nile virus infection. In some embodiments, the viral infection comprises an infection by a virus comprising a flavivirus M protein. In some embodiments, the viral infection comprises an infection by a flavivirus comprising a Dengue virus DPI protein. In some embodiments, the viral infection comprises an infection by a flavivirus comprising a West Nile virus MgM protein.
[068] According to some embodiments, the Dengue virus DPI channel blocker comprises plerixafor, an analog or a salt thereof. According to other embodiments, the West Nile virus channel blocker comprises plerixafor, an analog or a salt thereof.
[069] Plerixafor, as used herein, includes plerixafor (CAS: 110078-46-1, IUPAC: l-[[4- (1,4,8,11 -tetrazacyclo tetradec - 1 -y Imethy l)pheny 1] methyl] -1,4,8,11- tetrazacyclotetradecane), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof. Plerixafor, is described, for example, in U.S. Patent US20200268850A1.
[070] According to some embodiments, the invention provides a pharmaceutical composition comprising streptomycin, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a Dengue virus infection. In some embodiments, the viral infection comprises an infection by virus having a dengue virus DPI being an ion channel.
[071] According to some embodiments, the Dengue virus DPI channel blocker comprises streptomycin, an analog or a salt thereof.
[072] Streptomycin, as used herein, includes streptomycin (CAS: 57-92-1, IUPAC: 2- [(17?,27?,3S,47?,57?,6S)-3-(diaminomethylideneamino)-4-[(27?,37?,47?,55')-3- [(2S,3S,4S,57?,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4- formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[073] According to some embodiments, the invention provides a pharmaceutical composition comprising tranexamic acid, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a Dengue virus infection. In some embodiments, the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
[074] According to some embodiments, the Dengue virus DPI channel blocker comprises tranexamic acid an analog or a salt thereof.
[075] Tranexamic acid, as used herein, includes tranexamic acid (CAS: 701-54-2, IUPAC: 4-(aminomethyl)cyclohexane- 1 -carboxylic acid), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[076] According to some embodiments, the invention provides a pharmaceutical composition comprising CI- 1040, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a Dengue virus infection. In some embodiments, the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
[077] According to some embodiments, the Dengue virus DPI channel blocker comprises CI- 1040, an analog or a salt thereof.
[078] CI-1040, as used herein, includes CI-1040 (CAS: 212631-79-3, IUPAC: 2-(2-chloro- 4-iodoanilino)-A-(cyclopropylmethoxy)-3,4-difluorobenzamide), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[079] According to some embodiments, the invention provides a pharmaceutical composition comprising glecaprevir, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a Dengue virus infection. In some embodiments, the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
[080] According to some embodiments, the Dengue virus DPI channel blocker comprises glecaprevir, an analog or a salt thereof.
[081] Glecaprevir, as used herein, includes glecaprevir (CAS: 1365970-03-1; IUPAC: (l/?,14E,18/?,22/?,265,295)-26-fert-butyl-A-[(l/?,2/?)-2-(difluoromethyl)-l-[(l- methylcyclopropyl) sulfonylcarbamoyl] cyclopropyl] -13,13 -difluoro-24,27 -dioxo-2, 17,23- trioxa-4,l l,25,28-tetrazapentacyclo[26.2.1.03’12.05’10.018’22] hentriaconta-3,5,7,9,11,14- hexaene-29-carboxamide), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[082] According to some embodiments, the invention provides a pharmaceutical composition comprising kasugamycin, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a Dengue virus infection. In some embodiments, the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
[083] According to some embodiments, the Dengue virus DPI channel blocker is kasugamycin, an analog or a salt thereof.
[084] Kasugamycin, as used herein, includes kasugamycin (CAS: 6980-18-3; IUPAC: 2- amino-2-[(27?,3S,5S,67?)-5-amino-2-methyl-6-[(27?,3S,5S,6S)-2,3,4,5,6- pentahydroxycyclohexyl]oxyoxan-3-yl]iminoacetic acid), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[085] According to some embodiments, the invention provides a pharmaceutical composition comprising mesna, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a Dengue virus infection. In some embodiments, the viral infection comprises an infection by virus having a Dengue virus DPI being an ion channel.
[086] According to some embodiments, the Dengue virus DPI channel blocker comprises mesna, an analog or a salt thereof.
[087] Mesna, as used herein, includes mesna (CAS: 19767-45-4; IUPAC: sodiumssulf any lethanesulfonate), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[088] According to some embodiments, the invention provides a pharmaceutical composition comprising idasanutlin, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a West Nile virus infection. In some embodiments, the viral infection comprises an infection by virus having a West Nile MgM being an ion channel.
[089] According to some embodiments, the West Nile MgM channel blocker comprises idasanutlin, an analog or a salt thereof.
[090] Idasanutlin, as used herein, includes idasanutlin (CAS: 1229705-06-9; IUPAC: 4- [[(27?,3S,47?,5S)-3-(3-chloro-2-fhiorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2- dimethylpropyl)pyrrolidine-2-carbonyl] amino] -3 -methoxybenzoic acid), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[091] According to some embodiments, the invention provides a pharmaceutical composition comprising benzbromarone, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a West Nile virus infection. In some embodiments, the viral infection comprises an infection by virus having a West Nile MgM being an ion channel.
[092] According to some embodiments, the West Nile MgM channel blocker comprises benzbromarone, an analog or a salt thereof.
[093] Benzbromarone, as used herein, includes benzbromarone (CAS: 3562-84-3; IUPAC: (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-l-benzofuran-3-yl)methanone), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
[094] According to some embodiments, the invention provides a pharmaceutical composition comprising 5-azacytidine, an analog or a salt thereof, for treating a viral infection. In some embodiments, the viral infection comprises a West Nile virus infection. In some embodiments, the viral infection comprises an infection by virus having a West Nile MgM being an ion channel.
[095] According to some embodiments, the West Nile MgM channel blocker is 5- azacytidine, an analog or a salt thereof.
[096] 5 -Azacytidine, as used herein, includes 5-azacytidine (CAS: 320-67-2; IUPAC: 4- amino-l-[(27?,37?,4S,5S)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one), as well as pharmaceutically acceptable salts, solvates, hydrates, or mixtures thereof.
Pharmaceutical compositions
[097] As used herein, the terms “treatment” or “treating” of a disease, disorder, or condition encompasses alleviation of at least one symptom thereof, a reduction in the severity thereof, or inhibition of the progression thereof. Treatment need not mean that the disease, disorder, or condition is totally cured. To be an effective treatment, a useful composition herein needs only to reduce the severity of a disease, disorder, or condition, reduce the severity of symptoms associated therewith, or provide improvement to a patient or subject’s quality of life.
[098] As used herein, the terms “administering”, “administration” and like terms refer to any method which, in sound medical practice, delivers a composition containing an active agent to a subject in such a manner as to provide a therapeutic effect.
[099] As used herein, the terms “subject” or “individual” or “animal” or “patient” or “mammal” refers to any subject, particularly a mammalian subject, for whom therapy is desired, for example, a human.
[0100] In some embodiments, a therapeutically effective dose of the composition of the invention is administered. The term "therapeutically effective amount" refers to an amount of a drug effective to treat a disease or disorder in a mammal. The term “a therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. The exact dosage form and regimen would be determined by the physician according to the patient's condition.
[0101] The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The route of administration of the pharmaceutical compositions will depend on the disease or condition to be treated. Suitable routes of administration include, but are not limited to, parenteral injections, e.g., intradermal, intravenous, intramuscular, intralesional, subcutaneous, intrathecal, and any other mode of injection as known in the art. Although the bioavailability of peptides administered by other routes can be lower than when administered via parenteral injection, by using appropriate compositions it is envisaged that it will be possible to administer the compositions of the invention via transdermal, oral, rectal, vaginal, topical, nasal, inhalation and ocular modes of treatment. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention by any suitable
route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir.
[0102] In some embodiments, the composition of the invention comprising oral delivery. In some embodiments, the composition of the invention comprises an oral composition. In some embodiments, the composition of the invention further comprises orally acceptable carrier, excipient, or a diluent.
[0103] According to some embodiments, the Dengue virus DPI channel blocker is for use at a daily dose of 0.01 to 500 mg/kg.
[0104] According to some embodiments, the West Nile virus MgM channel blocker is for use at a daily dose of 0.01 to 500 mg/kg.
[0105] According to some embodiments, the Dengue virus DPI channel blocker comprises plerixafor or a salt thereof and is for use at a daily dose between about 0.1 mg/kg/day and about 10 mg/kg/day, 0.1 mg/kg/day and 5 mg/kg/day, and 0.1 mg/kg/day and 1 mg/kg/day.
[0106] According to some embodiments, the Dengue virus DPI channel blocker comprises streptomycin or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 100 mg/day, about 5 mg/kg/day and 60 mg/kg/day, and 10 mg/kg/day and 40 mg/kg/day.
[0107] According to some embodiments, the Dengue virus DPI channel blocker comprises tranexamic acid or a salt thereof and is for use at a daily dose of between about 1 mg//kg/day and about 100 mg/kg/day, about 1 mg/kg/day and 50 mg/kg/day, and 5 mg/kg/day and 40 mg/kg/day.
[0108] According to some embodiments, the Dengue virus DPI channel blocker comprises CI- 1040 or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 500 mg/kg/day, about 5 mg/kg/day and 400 mg/kg/day, and 40 mg/kg/day and 200 mg/kg/day.
[0109] According to some embodiments, the Dengue virus DPI channel blocker comprises glecaprevir or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 150 mg/kg/day, about 10 mg/kg/day and 100 mg/kg/day, and 1 mg/day and 10 mg/kg/day.
[0110] According to some embodiments, the Dengue virus DPI channel blocker comprises kasugamycin or a salt thereof and is for use at a daily dose of between about 1 mg/day and about 100 mg/kg/day, about 5 mg/kg/day and 50 mg/kg/day, and 10 mg/kg/day and 40 mg/kg/day.
[0111] According to some embodiments, the Dengue virus DPI channel blocker comprises mesna or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 100 mg/kg/day, about 5 mg/kg/day and 80 mg/kg/day, and 5 mg/kg/day and 50 mg/kg/day.
[0112] According to some embodiments, the West Nile virus MgM channel blocker comprises plerixafor or a salt thereof and is for use at a daily dose between about 0.1 mg/kg/day and about 10 mg/kg/day, 0.1 mg/kg/day and 5 mg/kg/day, and 0.1 mg/kg/day and 1 mg/kg/day.
[0113] According to some embodiments, the West Nile virus MgM channel blocker comprises idasanutlin or a salt thereof and is for use at a daily dose of between about 10 mg/kg/day and about 100 mg/kg/day, about 10 mg/kg/day and 50 mg/kg/day, and 5 mg/kg/day and 40 mg/kg/day.
[0114] According to some embodiments, the West Nile virus MgM channel blocker comprises benzbromarone or a salt thereof and is for use at a daily dose of between about 1 mg/kg/day and about 200 mg/kg/day, about 2 mg/kg/day and 150 mg/kg/day, and 3 mg/kg/day and 100 mg/kg/day.
[0115] According to some embodiments, the West Nile virus MgM channel blocker comprises 5-azacytidine or a salt thereof and is for use at a daily dose of between about 0.5 mg/kg/day and about 500 mg/day, about 1 mg/kg/day and 200 mg/day, and 1 mg/day and 100 mg/day.
[0116] In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier, adjuvant, or excipient.
[0117] As used herein, the term “carrier”, “adjuvant” or “excipient” refers to any component of a pharmaceutical composition that is not the active agent. As used herein, the term “pharmaceutically acceptable carrier” refers to non-toxic, inert solid, semi-solid liquid filler, diluent, encapsulating material, formulation auxiliary of any type, or simply a sterile aqueous medium, such as saline. Some examples of the materials that can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin, talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol, polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline, Ringer's solution;
ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations. Some non-limiting examples of substances which can serve as a carrier herein include sugar, starch, cellulose and its derivatives, powered tragacanth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols, alginic acid, pyrogen-free water, isotonic saline, phosphate buffer solutions, cocoa butter (suppository base), emulsifier as well as other non-toxic pharmaceutically compatible substances used in other pharmaceutical formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, stabilizers, antioxidants, and preservatives may also be present. Any non- toxic, inert, and effective carrier may be used to formulate the compositions contemplated herein. Suitable pharmaceutically acceptable carriers, excipients, and diluents in this regard are well known to those of skill in the art, such as those described in The Merck Index, Thirteenth Edition, Budavari et al., Eds., Merck & Co., Inc., Rahway, N.J. (2001); the CTFA (Cosmetic, Toiletry, and Fragrance Association) International Cosmetic Ingredient Dictionary and Handbook, Tenth Edition (2004); and the “Inactive Ingredient Guide,” U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Management, the contents of all of which are hereby incorporated by reference in their entirety. Examples of pharmaceutically acceptable excipients, carriers and diluents useful in the present compositions include distilled water, physiological saline, Ringer's solution, dextrose solution, Hank's solution, and DMSO. These additional inactive components, as well as effective formulations and administration procedures, are well known in the art and are described in standard textbooks, such as Goodman and Gillman’s: The Pharmacological Bases of Therapeutics, 8th Ed., Gilman et al. Eds. Pergamon Press (1990); Remington’s Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990); and Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins, Philadelphia, Pa., (2005), each of which is incorporated by reference herein in its entirety. The presently described composition may also be contained in artificially created structures such as liposomes, ISCOMS, slow-releasing particles, and other vehicles which increase the half-life of the peptides or polypeptides in serum. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. Liposomes for use with the presently described peptides are formed from standard vesicle-forming lipids which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally determined by considerations such as liposome size and stability in the blood. A variety of methods are available for preparing liposomes as reviewed, for example,
by Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York, and see also U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
[0118] The carrier may comprise, in total, from about 0.1% to about 99.99999% by weight of the pharmaceutical compositions presented herein.
Screening assays
[0119] By another aspect, there is provided a method of screening effectiveness of an agent in treating or preventing a Dengue virus infection. According to some embodiments, the method comprising providing a cell comprising a membrane permeabilized with Dengue DPI, contacting the cell with the agent, and determining effect of the agent on growth of the cell, wherein a substantial effect of the agent on cellular growth is indicative of the agent as being effective for treating or preventing a Dengue virus infection, thereby screening effectiveness of an agent in treating or preventing a Dengue virus infection.
[0120] In some embodiments, the method comprises a negative assay. In some embodiments, the cell is characterized by growth retardation due to the membrane permeabilized with Dengue DPI. In some embodiments, an agent that alleviates growth retardation is indicative as being effective for treating or preventing a Dengue virus infection.
[0121] In some embodiments, the method comprises a positive assay. In some embodiments, the cell is a K+-uptake deficient cell grown in low [K+] media experience growth, due to the channel formed by a Dengue DPI. In some embodiments, an agent that induces growth retardation is indicative as being effective for treating or preventing a Dengue virus infection.
[0122] In some embodiments, the method comprises performing both the negative assay and the positive assay.
[0123] In some embodiments, the method further comprises an acidity assay. In some embodiments, the cell is a pH-sensitive cell comprising a reporter gene or a protein product thereof, such as, but not limited to, green fluorescent protein (GFP). In some embodiments, H+ influx to a pH-sensitive cell, grown in media supplemented with an acidic solution, is induced. In some embodiments, an agent that elevates pH (reduces acidity) within the pH- sensitive cell is suitable for treating or preventing a Dengue virus infection.
[0124] In some embodiments, there is provided a method of screening effectiveness of an agent in treating or preventing a West Nile virus infection. According to some embodiments, the method comprising providing a cell comprising a membrane permeabilized with West Nile MgM, contacting the cell with the agent, and determining effect of the agent on growth of the cell, wherein a substantial effect of the agent on cellular growth is indicative of the
agent as being effective for treating or preventing a West Nile virus infection, thereby screening effectiveness of an agent in treating or preventing a West Nile virus infection.
[0125] In some embodiments, the method comprises a negative assay. In some embodiments, the cell is characterized by growth retardation due to the membrane permeabilized with West Nile MgM. In some embodiments, an agent that alleviates growth retardation is indicative as being effective for treating or preventing a West Nile virus infection.
[0126] In some embodiments, the method comprises a positive assay. In some embodiments, the cell is a K+-uptake deficient cell grown in low [K+] media experience growth, due to the channel formed by a West Nile MgM. In some embodiments, an agent that induces growth retardation is indicative as being effective for treating or preventing a West Nile virus infection.
[0127] In some embodiments, the method comprises performing both the negative assay and the positive assay.
[0128] In some embodiments, the method further comprises an acidity assay. In some embodiments, the cell is a pH-sensitive cell comprising a reporter gene or a protein product thereof, such as, but not limited to, green fluorescent protein (GFP). In some embodiments, H+ influx to a pH-sensitive cell, grown in media supplemented with an acidic solution, is induced. In some embodiments, an agent that elevates pH (reduces acidity) within the pH- sensitive cell is suitable for treating or preventing a West Nile virus infection.
[0129] Non-limiting examples for growing a bacterial cell applicable for the screening methods provided herein, include: Astrahan, P. et al., Acta 1808, 394-8 (2011); Santner, P. et al. Biochemistry 57, 5949-5956 (2018), and Taube, R., Alhadeff, R., Assa, D., Krugliak, M. & Arkin, I. T. PLoS One 9, el05387 (2014).
[0130] In some embodiments, the assay comprises determining susceptibility of the virus to develop resistance against the agent.
[0131] As used herein, the term "about" when combined with a value refers to plus and minus 10% of the reference value. For example, a length of about 1,000 nanometers (nm) refers to a length of 1,000 nm ± 100 nm.
[0132] It is noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a polynucleotide" includes a plurality of such polynucleotides and reference to "the polypeptide" includes reference to one or more polypeptides and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the
claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely", "only" and the like in connection with the recitation of claim elements or use of a "negative" limitation.
[0133] In those instances where a convention analogous to "at least one of A, B, and C, etc." is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., "a system having at least one of A, B, and C" would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase "A or B" will be understood to include the possibilities of "A" or "B" or "A and B."
[0134] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all subcombinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.
[0135] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
[0136] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
[0137] Generally, the nomenclature used herein, and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference. Other general references are provided throughout this document.
Materials and Methods
Bacteria-based channel assays
[0138] Three bacteria-based channel assays were employed for investigating the viroporin channel activity and blockers thereof. In all assays The MBP (Maltose binding protein) fusion purification system (New England BioLabs; Ipswich, MA, USA) was used, where Dengue Virus DPI and West Nile Virus MgM were expressed as chimera by fusion to the carboxy terminal of the maltose binding protein. Previous results have shown that utilizing this construct results in functional expression in bacteria .
Negative assay
[0139] Bacteria cultures (DH10B) were grown overnight and finally diluted 500 fold and again set to grow until their O.D.600 reached 0.2. From the culture 50 pl were added in 96- well flat-bottomed plates which was pre-treated with 50 pl of required staff. Induction was achieved by employing different concentration of isopropyl-P-d-1 -thiogalactopyranoside. A multi-plate incubator (infinite M200 pro from Tecan Group; Mannedorf, Switzerland or LogPhase 600 from BioTek; Santa Clara, CA, USA) was used to incubate the plates for 16
hours at 37 °C at a constant, shaking rate (700 rpm). Bacterial growth was monitored by measuring O.D.600 every 15 min. Duplicates, or triplicates were conducted for every measurement.
Positive assay
[0140] The positive assay employed the same protocol as the negative assay was but in this instance a K+-uptake deficient bacteria strain was used . Additionally, overnight growth was conducted in LB media in which 100 mM KC1 replaced NaCl.
[0141] The acidity assay is based on bacteria expressing a chromosomal copy of a pH sensitive GFP. Overnight bacterial cultures were diluted to 1:500 in LB media and subsequently grown to an O.D.600 of 0.6-0.8. Protein expression was induced by isopropyl- P-D-l- thiogalactopyranoside at different concentrations, as noted. After one hour of induction, the cells were diluted to an O.D.600 of 0.2 and pelleted at 3500 g for 10 min. Subsequently, the cells were resuspended in McILvaine Buffer, which contains 200 mM Na2HPO4 and 0.9% NaCl adjusted to pH 7.6 with 0.1 M citric acid. 200 pl of cell suspension were added to a 96-well plate (Nunclon f96 Microwell Black Polystyrene, Thermo Fisher Scientific; Waltham, MA, USA), each well containing 30 pl of McILvaine Buffer. The plate included three wells with McILvaine buffer and three with culture without induction as control. The fluorescent measurements were carried out at an ambient temperature in a microplate reader (Infinite F200 Pro, Tecan Group; Mannedorf, Switzerland) with two pairs of bandpass filters: 520 nm emission filter and 390 and 466 nm excitation filters. At the starting point, 70 pl of 300 mM citric acid was added to the bacterial culture, and a fluorescent read-out was taken for 30 s for each wavelength. Finally, proton concentration was calculated from the ratio of two wavelengths.
Chemical Screening
[0142] A chemical library of 2,839 compounds was purchased from MedChem Express (HY- L035, Monmouth Junction, NJ, USA). All chemicals were screened at 100 pM using the negative screening at first, whereby 100 pM isopropyl-P-D-l-thiogalactopyranoside was used to induce DPI and MgM expression. Bacteria without isopropyl-P-D-1- thiogalactopyranoside (z.e., no protein induction) were used as a positive control, while bacteria that received only DMSO served as the negative control. Drugs that increased bacterial growth up to a certain threshold were selected for further duplicate analyses. Subsequently, drugs that passed duplicate analysis in the negative assays were examined by positive assay, where 5 pM and 10 pM isopropyl-P-D-l-thiogalactopyranoside were used to induce DPI and MgM expression, respectively. Compounds that passed the negative and
positive assays were subjected to dose-response analyses and fluorescence-based assays. Finally, the negative assay tested the additive effects of drugs by employing equal concentrations of all possible combinations.
Chemicals
[0143] Isopropyl-P-d-1 -thiogalactopyranoside was purchased from Biochemika-Fluka (Buchs, Switzerland). All other chemicals were purchased from Sigma- Aldrich laboratories (Rehovot, Israel).
Bacterial growth media
[0144] Lysogeny broth (LB) was used for most of the cases only LBK was used for positive assay, where NaCl is replaced with KCL at lOgm/lt. All media contained ampicilin at 100 g/ml.
Cell viability assay
[0145] Growth of Vero E6 cells was tested in the presence of Dengue virus (type 1, BC89/94). Cells were infected with a muliplicity of infection (MOI) of 3, and their viability was monitored by MTS post five days of infection. At time 0, different drugs were added (each diluted in 0.1% DMSO) at a concentration of 10 pM. Results were normalized relative to uninfected cells (100%) and cells that received only 0.1% DMSO (0%).
EXAMPLE 1
Bacteria-based assays for assessment of ion channels activity
[0146] In order to evaluate the activity of both viroporins, the inventors used bacteria-based assays in which the channel’s functionality changes the bacteria’s phenotype. The advantages of the assays are that they are amenable to high-throughput screening, and the ease of genetic manipulations in bacteria enables a rapid transition from one sequence/variant to another. Finally, these assays have been tested on numerous viroporins from various viruses (Assa, D. et al. J Mol Biol 2016, 428, 4209-4217, Astrahan, P. et al. 2011, 1808, 394-398, Taube, R, PLoS One 2014, 9, el05387, Tomar, P.P.S. et al. Viruses 2019, 11, Tomar, P.P.S. et al. Viruses 2021, 13, Tomar, P.P.S. et al. Pharmaceuticals (Basel) 2021, 14, Tomar, P.P.S. et al. Krugliak, M.; Singh, A.; Arkin, I.T. Biomedicines 2022).
Negative assay
[0147] The first assay used to characterize both viroporins is one in which the protein is expressed at increasing levels in bacteria. As seen in other channels, elevated expression levels are detrimental to bacterial growth due to excessive permeabilization of the bacterial
inner membrane. Therefore, in this assay, the viral protein eponymously impacts bacteria negatively.
[0148] As seen in Figure 1, both proteins are able to retard bacterial growth appreciably. At inducer concentrations of 50-100 pM the growth rate is roughly half of what is observed without induction. Finally, the inventors recognize that spurious factors can contribute to toxicity upon heterologous protein expression in bacteria. Therefore the inventors employed two additional bacteria-based assays to evaluate the channel activity of the viral proteins.
Positive assay
[0149] The second bacteria-based assay that was employed was reciprocal in nature to the negative assay listed above. K+-uptake deficient bacteria are incapable of growing in regular bacteriological media unless it is enriched with potassium. However, the bacteria are able to thrive in low K+ media if they express a channel capable K+ transport. Hence, in this instance the activity of the channel impacts growth positively.
[0150] Results shown in Figures 2A-2D indicate clearly that both viroporins are able to enhance the growth of K+-uptake deficient bacteria. The experiments were repeated at several different K+ concentrations in order to demonstrate the reproducible nature of the effect. Note that in this assay the channel was expressed at a low level, since higher levels were once more detrimental to the bacteria, as seen in Figures 2C-2D.
Acidity assay
[0151] The final assay that was employed measured H+ conductivity by using bacteria that express a pH-sensitive GFP. In this assay, an acidic solution is injected into the media while monitoring bacterial fluorescence that is indicative of its cytoplasmic pH. A change in fluorescence would indicate H+- flux due to a channel conductivity. Results shown in Figure 3 demonstrate that both viroporins were able to facilitate H+ transport with Dengue Virus DPI exhibiting higher activity than West Nile Virus MgM.
Blocker screening
[0152] Following confirmation of channel activity of both viral proteins, the inventors sought to identify drugs that could block their function. The negative assay described above was empolyed and a 2,839 repurposed drug library was screened. The inventors subsequently followed by cross-checking every hit using the positive and pH-based assays. In the negative assay, a successful hit is expected to increase bacterial growth by abrogating the detrimental impact the viroporin has. In contrast, in the positive assay, successful blockers would impair bacterial growth since they would counteract the beneficial effect of the viral channel.
[0153] The reciprocal nature of both assays decreases the possibility of erroneous results. Specifically, compounds were classified as hits only if they increased bacterial growth in the negative assay while concomitantly reducing growth in the positive assay.
[0154] The results of the negative assay screen are shown Figures 4A-4B in which seven blockers were identified against Dengue Virus DPI and four against West Nile Virus MgM. Subsequently, the positive assay was employed to examine the potency of the hits identified in the negative assay: out of the seven blockers active against Dengue Virus DPI, four were shown to be active in the positive assay, conducted herein (Figure 4C). In contrast, all hits in the negative assay against West Nile Virus MgM were confirmed in the positive assay (Figure 4D).
[0155] Finally, the hits identified in the negative assay were examined in the acidity assay: Out of the seven blockers active against Dengue Virus DPI, six were confirmed in the acidity assay (Figure 4E). Once more, all hits from the negative and positive assay against West Nile Virus MgM were active in the acidity assay (Figure 4F).
[0156] The final step in the screening process involved dose-response analyses of the compounds that passed the negative and positive assays for each viroporin: plerixafor, streptomycin, tranexamic acid, and CI-1040 against Dengue Virus DPI, and idasanutlin, benzbro-marone, 5-azacytidine, and plerixafor against West Nile Virus MgM. The results are depicted in Figures 5A-5D, and the fitted inhibitory contestants are provided in Figure 6.
Combination testing
[0157] The inventors next sought to determine potential additivity or synergism between the different hits. To that end, they examined all possible combinations of drugs that were active against Dengue Virus DPI and West Nile Virus MgM channels in equal concentrations. From Figure 7B it can be seen that several Dengue Virus DPI blocker combinations, like tranexamic acid + mesna, kasugamycin + CI- 1040, and kasugamycin + tranexamic acid exhibited additivity. Tranexamic acid + mesna in particular, demonstrated 98% enhancement of growth, whereas the impact of individual components was lower (32% and 82% for tranexamic acid and mesna, respectively). All the compounds that were combined with plerixafor exhibited better activity due to its masking effect. In the case of West Nile Virus MgM (Figure 7A), combinations such as plerixafor + idasanutlin (128%) and plerixafor + benzbromarone (181%) exhibited additivity, while the effect of combining 5-azacytidine with idasanutlin (105%) reduced activity.
Cell viability
[0158] Further, the invenotrs have examined cell viability Vero E6 cells infected with the Dengue virus. The results show that Plerixafor, Mesna, Glecaprevir, Kasugamycin, and Streptomycin presented a clear anti-dengue virus activity, as provided by increased cell viability in vitro (Figure 8).
[0159] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Claims
1. A method of treating or preventing a flavivirus virulence in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a flavivirus M protein channel blocker, thereby treating or preventing flavivirus virulence in said subject.
2. A method of preventing flavivirus entry, uncoating and/or release from a cell, the method comprising contacting said cell with a flavivirus M protein channel blocker, thereby preventing a flavivirus cell entry, uncoating and/or release from said cell.
3. The method of claim 2, wherein said cell is a cell of a subject, and wherein said contacting is administering to the subject.
4. The method of any one of claims 1 to 3, wherein said subject is a subject infected or suspected as being infected by a flavivirus virus.
5. The method of any one of claims 1 to 4, wherein said flavivirus is a Dengue virus, and said flavivirus M protein channel blocker is a Dengue virus DPI channel blocker.
6. The method of any one of claims 1 to 4, wherein said flavivirus is a West Nile virus, and said flavivirus M protein channel blocker is a West Nile virus MgM channel blocker.
7. The method of claim 5, wherein said Dengue virus DPI channel blocker is at least one molecule selected from the group consisting of: plerixafor, glecaprevir streptomycin, mesna, kasugamycin, tranexamic acid, CI- 1040, a salt thereof, and any combination thereof.
8. The method of claim 6, wherein said West Nile virus MgM channel blocker is at least one molecule selected from the group consisting of: idasanutlin, benzbromarone, 5- azacytidine, plerixafor, a salt thereof, and any combination thereof.
9. The method of any one of claims 1, and 3-8, wherein said flavivirus M protein channel blocker is for use at a daily dose of 0.01 to 500 mg/kg per body weight of said subject.
10. A pharmaceutical composition comprising a flavivirus M protein channel blocker for use in treating or preventing flavivirus virulence in a subject in need thereof.
11. The pharmaceutical composition of claim 10, wherein said flavivirus is a Dengue virus and wherein said M protein channel blocker a DPI channel blocker.
12. The pharmaceutical composition of claim 10, wherein said flavivirus is a West Nile virus and wherein said M protein channel blocker a MgM channel blocker.
13. A pharmaceutical composition comprising a flavivirus M protein channel blocker for use in preventing a flavivirus cell entry, uncoating and/or release from a cell.
14. The pharmaceutical composition of claim 13, wherein said flavivirus M protein channel blocker comprises a Dengue virus DPI channel blocker, and is for use in preventing a Dengue virus cell entry, uncoating and/or release from said cell.
15. The pharmaceutical composition of claim 13, wherein said flavivirus M protein channel blocker comprises a West Nile virus MgM channel blocker, and is for use in preventing a West Nile virus cell entry, uncoating and/or release from said cell.
16. The pharmaceutical composition of claim 11 or 14, wherein said Dengue virus DPI channel blocker is at least one molecule selected from the group consisting of: plerixafor, glecaprevir streptomycin, mesna, kasugamycin, tranexamic acid, CI- 1040, a salt thereof, and any combination thereof.
17. The pharmaceutical composition of claim 12 or 15, wherein said West Nile virus MgM channel blocker is at least one molecule selected from the group consisting of: idasanutlin, benzbromarone, 5-azacytidine, plerixafor, a salt thereof, and any combination thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263358659P | 2022-07-06 | 2022-07-06 | |
US63/358,659 | 2022-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024009307A1 true WO2024009307A1 (en) | 2024-01-11 |
Family
ID=89454516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2023/050703 WO2024009307A1 (en) | 2022-07-06 | 2023-07-06 | Viroporins blockers/inhibitors as anti-flaviviruses agents |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024009307A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
US20070135525A1 (en) * | 2005-11-28 | 2007-06-14 | Liang Hao Y | Materials and methods for treating viral infections |
WO2009049115A1 (en) * | 2007-10-11 | 2009-04-16 | University Of Maryland | Methods for the treatment of viral conditions |
-
2023
- 2023-07-06 WO PCT/IL2023/050703 patent/WO2024009307A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
US20070135525A1 (en) * | 2005-11-28 | 2007-06-14 | Liang Hao Y | Materials and methods for treating viral infections |
WO2009049115A1 (en) * | 2007-10-11 | 2009-04-16 | University Of Maryland | Methods for the treatment of viral conditions |
Non-Patent Citations (5)
Title |
---|
ANROOPB NAIR, SHERY JACOB: "A simple practice guide for dose conversion between animals and human", JOURNAL OF BASIC AND CLINICAL PHARMACY, INDIA, vol. 7, no. 2, 1 May 2016 (2016-05-01), India , pages 27, XP055627116, ISSN: 0976-0105, DOI: 10.4103/0976-0105.177703 * |
Brown et al. Inhibitors of the Small Membrane (M) Protein Viroporin Prevent Zika Virus Infection. bioRxiv. 2021 Mar 12:2021-03 [online], [retrieved on 2023-09-21]. Retrieved from the Internet <URL: https://doi.org/10.1101/2021.03.11.435022> <DOI: 10.1101/2021.03.11.435022> (2021/03/12) * |
LAHIRI HIYA, ARKIN ISAIAH T.: "Searching for Blockers of Dengue and West Nile Virus Viroporins", VIRUSES, MDPI, CH, vol. 14, no. 8, CH , pages 1750, XP093126926, ISSN: 1999-4915, DOI: 10.3390/v14081750 * |
MCCANDLESS ERIN E., ZHANG BO, DIAMOND MICHAEL S., KLEIN ROBYN S.: "CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 105, no. 32, 12 August 2008 (2008-08-12), pages 11270 - 11275, XP093126920, ISSN: 0027-8424, DOI: 10.1073/pnas.0800898105 * |
TOMAR PST, KRUGLIAK M, SINGH A, ARKIN IT: "Zika M—A Potential Viroporin: Mutational Study and Drug Repurposing", BIOMEDICINES, MDPI AG, vol. 10, no. 3, 10 March 2022 (2022-03-10), pages 641, XP093043416, DOI: 10.3390/biomedicines10030641 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Masumoto et al. | ASC is an activating adaptor for NF-κB and caspase-8-dependent apoptosis | |
Waxman et al. | IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2–induced Bak interactions with mitofusions | |
US20200318081A1 (en) | Vectors with promoter and enhancer combinations for treating phenylketonuria | |
US9539307B2 (en) | Compositions and methods for treating amyotrophic lateral sclerosis | |
EP3247375B1 (en) | Anti-senescence compounds and uses thereof | |
Wang et al. | IL-17 potentiates neuronal injury induced by oxygen–glucose deprivation and affects neuronal IL-17 receptor expression | |
US20230381290A1 (en) | Methods for treatment of and prophylaxis against inflammatory disorders | |
ES2753436T3 (en) | GATA-3 inhibitors for use in treating Th2-mediated asthma | |
Liverani et al. | Protein Kinase C-delta Inhibition is Organ-Protective, Enhances Pathogen Clearance and Improves Survival in Sepsis | |
US10857201B2 (en) | NNIF and nNIF-related peptides and related methods | |
Zhou et al. | Tat-NTS peptide protects neurons against cerebral ischemia-reperfusion injury via ANXA1 SUMOylation in microglia | |
WO2024009307A1 (en) | Viroporins blockers/inhibitors as anti-flaviviruses agents | |
Cui et al. | TSG-6 alleviates cerebral ischemia/reperfusion injury and blood-brain barrier disruption by suppressing ER stress-mediated inflammation | |
Miossec et al. | Cerebral phaeohyphomycosis due to Cladophialophora bantiana in a French Guianese child | |
CA3177537A1 (en) | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents | |
US11592445B2 (en) | OLFR90 specificity and methods of detection | |
US20230190769A1 (en) | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents | |
Dolatabadi et al. | Phaeohyphomycosis caused by Neoscytalidium dimidiatum in a COVID-19 patient | |
WO2023144830A1 (en) | Zika m protein blockers as anti-zika virus agents | |
US11324801B2 (en) | NNIF and nNIF-related peptides and related methods | |
Zhang et al. | Manf Enhances the Pyroptosis Inhibition of Bone Marrow-derived Mesenchymal Stem Cells to Relieve Cerebral Infarction Injury | |
WO2022113069A1 (en) | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents | |
Li et al. | Rhinocerebral mucormycosis secondary to acute lymphoblastic leukemia: a case report | |
MATSUI et al. | Antitumor effect of violacein on colorectal cancer cells | |
EP3738972A1 (en) | Parvolysine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23835057 Country of ref document: EP Kind code of ref document: A1 |